Valuation Rani Therapeutics Holdings, Inc.
Stocks
RANI
US7530181004
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 0.8426 USD | +2.51% |
|
-2.62% | -37.59% |
Company Valuation: Rani Therapeutics Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 322.3 | 145.8 | 85.92 | 45.64 | 131.7 | 97.26 | - | - |
| Change | - | -54.75% | -41.09% | -46.89% | 188.57% | -26.15% | - | - |
| Enterprise Value (EV) | 322.3 | 77.02 | 37.38 | 45.64 | 131.7 | 97.26 | 97.26 | 97.26 |
| Change | - | -76.1% | -51.46% | 22.08% | 188.57% | -26.15% | 0% | 0% |
| P/E | -38x | -4.61x | -2.5x | -1.3x | -3x | -4.86x | -4.43x | -5.38x |
| PBR | - | 7.91x | - | - | - | - | - | - |
| PEG | - | -0x | -0.64x | 0.1x | 0.1x | 0.1x | -0.46x | 0.3x |
| Capitalization / Revenue | 119x | - | - | 44.4x | 80.6x | 15.5x | 14.7x | 6.99x |
| EV / Revenue | 0x | - | - | 0x | 0x | 15.5x | 14.7x | 6.99x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.63x | -2.28x | -2.29x |
| EV / FCF | - | - | - | - | - | -2.43x | -2.11x | -2.03x |
| FCF Yield | - | - | - | - | - | -41.1% | -47.3% | -49.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.43 | -1.28 | -1.33 | -1.05 | -0.45 | -0.1733 | -0.19 | -0.1567 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2.717 | - | - | 1.028 | 1.633 | 6.258 | 6.632 | 13.91 |
| EBITDA | -51.1 | -62.9 | -65.28 | -52.29 | - | - | - | - |
| EBIT 1 | -51.6 | -63.45 | -66.1 | -49.6 | -38.31 | -36.95 | -42.68 | -42.56 |
| Net income 1 | -8.331 | -30.59 | -33.97 | -30.02 | -29.67 | -31.46 | -36.73 | -34.4 |
| Net Debt | - | -68.83 | -48.54 | - | - | - | - | - |
| Reference price 2 | 16.3500 | 5.9000 | 3.3200 | 1.3700 | 1.3500 | 0.8426 | 0.8426 | 0.8426 |
| Nbr of stocks (in thousands) | 19,712 | 24,720 | 25,880 | 33,312 | 97,551 | 115,425 | - | - |
| Announcement Date | 3/31/22 | 3/22/23 | 3/20/24 | 3/31/25 | 3/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.74x | - | - | - | 94.88M | |
| 20.07x | 7.08x | 14.22x | 1.48% | 68.24B | |
| 32.07x | 9.28x | 44.74x | 0.04% | 62.23B | |
| -77.91x | 15.04x | -72.53x | -.--% | 27.8B | |
| 28.78x | 6.1x | 15.83x | -.--% | 24.86B | |
| -14.55x | 5.23x | -6.58x | -.--% | 24.22B | |
| 26.34x | 4.96x | 16.5x | -.--% | 19.36B | |
| 49.79x | 18.37x | 37.27x | 0.3% | 17.28B | |
| 1249.7x | 36.02x | 786.01x | -.--% | 14.46B | |
| 17.74x | 5.28x | 12.34x | -.--% | 14.23B | |
| Average | 132.73x | 11.93x | 94.20x | 0.2% | 27.28B | |
| Weighted average by Cap. | 77.93x | 10.15x | 53.10x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RANI Stock
- Valuation Rani Therapeutics Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
